New Diagnostic Aids for Melanoma

Laura Korb Ferris, MD, PhD*, Ryan J. Harris, MD

KEYWORDS
- Melanoma detection • Technology • Imaging • Biopsy • Automated diagnosis

KEY POINTS
- The incidence of melanoma is continuing to increase.
- Current methods commonly fail to diagnose melanoma at an early stage.
- Use of dermatoscopy has improved our diagnostic capabilities, but is highly user dependent and commonly misses the diagnosis.
- Recent advances have lead to new diagnostic technologies such as confocal scanning laser microscopy, MelaFind, SIAscopy, noninvasive genomic detection, and many others.
- Systems such as MelaFind are being created to provide an automated diagnosis to improve diagnostic accuracy and decrease the need for biopsy of benign lesions.
- Several barriers to implementation exist, including cost, time needed to become competent in use of new technologies, and lack of insurance reimbursement for use of new modalities.
- Proper implementation of new technologies will, it is hoped, lead to earlier diagnosis of melanoma, decreased mortality and morbidity, fewer biopsies of benign lesions, and decreased cost to the health care system.

INTRODUCTION

According to estimates, there will be approximately 70,000 new cases of melanoma and 8800 subsequent deaths in 2011. For 2012 the estimates are 76,250 cases and 9180 deaths.¹ The incidence of melanoma has been steadily increasing and has doubled in recent decades.² For lesions with a depth of less than 1 mm, surgical excision is usually curative and 5-year survival rate is 93% to 97%.³ By contrast, distant metastatic melanoma has an extremely poor prognosis and 5-year survival ranges from 10% to 20%, depending on location of the metastasis.³ Detection of melanoma at an early stage is critical for improving the survival rate. In addition to decreased survival of late-stage versus early-stage melanoma, the cost of treating a late-stage melanoma is dramatically higher.

Recent estimates show the total costs of in situ tumors to be around $4700, whereas a stage IV melanoma has a total cost of approximately $160,000.⁴ The cost of treating late-stage melanoma is likely to increase with the implementation of newly approved treatments such as ipilimumab, which costs about $120,000 for a full treatment.

Despite advances in diagnostic aids such as dermatoscopy, detection has remained a significant challenge, and improved methods of accurately diagnosing melanoma are needed. Studies have shown that even for expert dermoscopists, accurately diagnosing melanoma, particularly in small-diameter lesions, is very challenging, with one study showing a biopsy sensitivity of 71% for melanomas of size less than 6 mm.⁵ To measure specificity, numerous studies have looked at biopsy ratios (ie,
the number of biopsies of benign lesions performed to make the diagnosis of one skin cancer), and numbers vary widely. On the low end, a study from a specialized pigmented lesion clinic showed a biopsy ratio of approximately 5:1 (5 benign lesions per melanoma biopsied). A recent retrospective study involving 8 practitioners at a single institution had a biopsy ratio of 15:1. On the high end, a study involving a single physician over a 14-year period showed a biopsy ratio of more than 500:1 in patients with no history of melanoma. Given these challenges, new diagnostic aids that could help increase both sensitivity and specificity of biopsies would be of great benefit to patients and physicians. Such improvements (Table 1) have the potential to lead to increased diagnosis of early lesions, which would improve survival and lower the overall cost of treating melanoma. In addition, improved diagnostic techniques would lead to fewer biopsies and decreased morbidity to patients.

**ESTABLISHED METHODS**

*Physician and Patient Detection of Malignant Melanoma*

Multiple studies have tried to assess who initially detects melanomas, with most finding that the majority of melanomas are detected by the patient. Patient education, including the ABCDEs (Asymmetry, Border irregularity, Color variegation, Diameter of >6 mm, and Evolution) of melanoma will always be an important part of helping patients to diagnose melanoma. In addition, regular self-examinations of the skin should be encouraged, as they have been associated with detection of thinner melanomas and may reduce mortality. Self detection seems to be most successful in younger patients, as increased age has been associated with increased Breslow thickness in patients who have discovered melanoma by self examination. Physician-detected melanomas, particularly melanomas detected by dermatologists, tend to be thinner.

**Dermatoscopy**

Dermatoscopy, covered in depth by Rao and Ahn elsewhere in this issue, has been widely used by dermatologists to improve their abilities to accurately diagnose melanoma, and has been shown to improve early detection of melanoma while reducing unnecessary biopsies. A major drawback to dermatoscopy is that it is highly user dependent and varies with experience. Despite the advantages of using dermatoscopy, only about 60% of dermatologists in the United States are trained in its use, and fewer than half report using dermatoscopy daily (Fig. 1).

**Temporal Analysis of the Skin**

In addition to dermatoscopy alone, temporal analysis of the skin is commonly used. Individual lesions can be followed serially with dermatoscopy and/or photography. Total-body photography can be used to monitor for new or changing lesions, particularly in high-risk patients or patients with a large number of nevi. Temporal analysis has been shown to increase the sensitivity of melanoma detection when compared with dermatoscopy alone. A perceived benefit of total-body photography would be to decrease the biopsy rate, and indeed this has been demonstrated in some studies, although others have failed to show any noticeable change in number of biopsies performed. Total-body photography seems to be most useful in older patients, as one study showed that in patients younger than 50 years fewer than 1% of new lesions identified by photography turned out to be melanoma, whereas in patients older than 50 years 30% of new lesions were melanomas on biopsy. Total-body photography has the limitation of being time consuming and laborious. Also, costs can run as high as $500 per person and are not typically covered by insurance. Imaging technologies including MoleMax (Derma Medical Systems, Vienna, Austria) and FotoFinder (FotoFinder Systems, Inc, Columbia, MD, USA) are computerized systems used to help the clinician to more rapidly and efficiently perform total-body cutaneous photography and dermatoscopy of individual lesions. MoleMax has software that analyzes pigmented lesions and provides a scoring system based on established criteria to aid clinicians in evaluating concerning lesions. The FotoFinder system also has software that aids in the detection of new nevi by comparing baseline photos with those taken at a follow-up visit, as well as software that rates the likelihood that a pigmented lesion is a melanoma. However, no large peer-reviewed studies have validated the accuracy of these systems.

**RECENT ADVANCES**

*Confocal Scanning Laser Microscopy*

Confocal scanning laser microscopy (CSLM) is a noninvasive imaging technology that provides in vivo images of the epidermis and papillary dermis in real time. There are currently 2 forms of CSLM in use: reflectance mode, which is primarily used in clinical practice, and fluorescence mode, used primarily in research. Reflectance confocal microscopy (RCM) relies on the inherent reflective properties of tissue structures, whereas fluorescence CSLM relies on fluorescent dyes to provide contrast for images. The contrast seen in RCM
## Table 1
Comparison of technologies in melanoma diagnosis

<table>
<thead>
<tr>
<th>Technology</th>
<th>Sensitivity (%)</th>
<th>Specificity (%)</th>
<th>Advantages</th>
<th>Disadvantages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Confocal scanning laser microscopy</td>
<td>88–98&lt;sup&gt;32–34&lt;/sup&gt;</td>
<td>83–98&lt;sup&gt;32–34&lt;/sup&gt;</td>
<td>Provides a “virtual biopsy” of concerning lesions. Low incremental cost per lesion after initial investment</td>
<td>Accuracy is user dependent; imaging depth only 300 μm; imaging system is expensive</td>
</tr>
<tr>
<td>MelaFind</td>
<td>98&lt;sup&gt;42&lt;/sup&gt;</td>
<td>10&lt;sup&gt;42,a&lt;/sup&gt;</td>
<td>Provides automated diagnosis, minimizing user dependence</td>
<td>Cost of imaging is $150, which must be covered by the patient</td>
</tr>
<tr>
<td>SIAscope</td>
<td>83–91&lt;sup&gt;38&lt;/sup&gt;</td>
<td>80–91&lt;sup&gt;38,39&lt;/sup&gt;</td>
<td>Provides high-resolution images of melanin, hemoglobin, and collagen content in the epidermis and papillary dermis</td>
<td>Accuracy is user dependent; diagnostic features may classify many benign lesions as malignant</td>
</tr>
<tr>
<td>Epidermal genetic information retrieval</td>
<td>100&lt;sup&gt;48&lt;/sup&gt;</td>
<td>88&lt;sup&gt;48&lt;/sup&gt;</td>
<td>Minimal special equipment or investment required up front</td>
<td>Samples must be sent to distant laboratory, delaying diagnosis</td>
</tr>
<tr>
<td>Electrical impedance spectroscopy</td>
<td>91–95&lt;sup&gt;52,53&lt;/sup&gt;</td>
<td>49–64&lt;sup&gt;52,53&lt;/sup&gt;</td>
<td>Provides automated diagnosis</td>
<td>Can be technically challenging; can take up to 5 minutes per lesion for evaluation</td>
</tr>
</tbody>
</table>

<sup>a</sup> Lesions evaluated in this study were enriched by preselection from a general population. Lesions were already scheduled for a biopsy because of high concern for melanoma, resulting in a lower specificity in comparison with other studies performed in lesions that were not preselected.
images is due to the naturally occurring variations in
refractive index of organelles and other structures
within the skin. Melanin granules have a high refrac-
tive index, which causes more light to be reflected
back to the confocal microscope. Thus areas of
higher melanin concentration will appear as bright
areas on a confocal image (Fig. 2). When used by
those properly trained in confocal use, lesions
can be evaluated based on characteristics such
as cellular atypia, uniformity of pigment distribu-
tion, loss of keratinocyte borders, and rate of blood
flow to help distinguish malignant from benign
lesions. One of the unique features of CSLM is its
ability to detect amelanotic melanoma because of
the presence of melanosomes and rare melanin
granules.29

CSLM works by intensely focusing a low-power
laser beam on a specific point in the skin. Light
from that point is then reflected from structures
within the skin, and passes through a pinhole-sized
aperture to a detection apparatus. The reflected light
is transformed into an electrical signal to create
a 3-dimensional image from the scanned horizontal
sections.30 Imaging depth is related to the
wavelength of light used, with longer wavelengths al-
lowing deeper imaging. RCM uses a near-infrared
830-nm laser that provides an imaging depth of
250 to 300 μm in normal skin, allowing visualization
to the level of the superficial dermis.28 The images
provide 1 to 2 μm of lateral resolution and 3 to 5
μm of axial resolution.31 This resolution is com-
parable with that of standard pathology, which is typi-
cally based on 5-μm thin sections. CSLM has
potential to provide a “virtual biopsy” of concerning
skin lesions. Advantages of CSLM are that, like der-
matoscopy, it is noninvasive and allows rapid
imaging of multiple lesions, and can be used to
follow lesions over time. CSLM is also similar to der-
matoscopy in that it requires the reader’s interpreta-
tion and is thus user dependent. Training required to
accurately use CSLM has been reported to be less
than that required for dermatoscopy, with subjects
showing ability to correctly diagnose images of
lesions from a test set after only 30 minutes of
instruction in one study.32

CSLM has demonstrated high sensitivity and
specificity in diagnosing melanoma from benign
pigmented lesions. One study involving a test set
of 27 melanomas and 90 benign nevi with images
evaluated by 5 independent observers showed
sensitivity of 88.15% and specificity of 97.6%.32
A retrospective study of 3709 unselected CSLM
melanocytic tumor images coming from 50 benign
nevi and 20 melanomas showed sensitivity and
specificity of 97.5% and 99%, respectively.33 In
comparison with standard dermatoscopy, another
prospective study showed sensitivity and speci-
cicity of CSLM to be 97.3% and 83%, respectively,
compared with sensitivity and specificity of 89.2%
and 84.1% for dermatoscopy.34 This study,
however, involved only a single observer and eval-
uated 37 melanomas and 88 nevi.

CSLM has been tested with diagnostic
imaging analysis for fully automated diagnosis,
and in the future such a system could possibly improve diagnostic accuracy and decrease user dependence.\textsuperscript{35–37} CSLM is also limited by its cost. A commercially available unit costs approximately $50,000. Although the upfront cost of the device is high, the supplies to image individual lesions cost only about $1 per lesion, allowing imaging of multiple lesions with minimal increased cost to the patient per lesion.

Advances in CSLM technology continue to make it a more useful diagnostic tool. Newer devices use a single optical fiber to both illuminate and detect the laser light in place of the pinhole aperture detector found in earlier CSLM devices. This improvement has led to miniaturization of the confocal scanner into a flexible and more user-friendly handheld device. Multiple CSLM units are available and have Food and Drug Administration (FDA) 510(k) clearance, including the VivaScope 1500 and the handheld VivaScope 3000 (Lucid, Inc, Rochester, NY, USA).

**Multispectral Imaging**

The SIAscope (Spectrophotometric Intracutaneous Analysis, made by Biocompatibles, Farnham, Surrey, UK) emits radiation ranging from 400 to 1000 nm, and provides the user with 8 narrow-band spectrally filtered images that demonstrate the vascular composition and pigment network of a lesion. This multispectral imaging technology has FDA 510(k) clearance and uses a handheld imager to provide microarchitectural information for concerning lesions. The SIAscope measures levels of 3 chromophores (melanin, blood, and collagen) contained in the epidermis and papillary dermis. It is also able to show if melanin is confined to the epidermis, or whether it has penetrated into the deeper dermis. The clinician then interprets these images to determine whether a biopsy is necessary. In a study of 384 lesions, SIAscopy was found to have a sensitivity of 82.7% and specificity of 80.1%.\textsuperscript{38} However, a larger study showed that SIAscopy had similar sensitivity and specificity to dermatoscopy performed by experienced dermatologists, and thus did not provide sufficient benefit in diagnosing melanoma to warrant its use.\textsuperscript{39} One of the major criticisms of SIAscopy is that it uses features in its diagnostic classification that are common to benign lesions, such as seborrheic keratoses and hemangiomas, which causes many benign lesions to be classified as suspicious.\textsuperscript{40} A recent study sought to develop a scoring system to correctly classify lesions and allow use of SIAscopy in a primary care setting.\textsuperscript{40} The scoring system is still early in its development and needs further improvement and validation, but such a system could provide primary care physicians with a useful tool to screen a larger population of patients, with referral to a dermatologist for suspicious lesions.

As most imaging modalities require user interpretation and are thus prone to varying levels of accuracy based on user experience, attempts have been made to create automated imaging systems to improve diagnostic accuracy. MelaFind (MELA Sciences, Inc, Irvington, NY, USA) is a handheld imager that evaluates lesions with multispectral images in 10 different spectral bands, from blue (430 nm) to near infrared (950 nm). The images are processed with proprietary software, which generates a 10 digital image sequences in less than 3 seconds. The software determines the border of the lesion and analyzes the lesion for asymmetry, color variation, perimeter changes, texture changes, and wavelet maxima (Fig. 3).\textsuperscript{41} The MelaFind device then provides the user with a recommendation of whether or not to perform a biopsy based on this analysis. The algorithm for determining biopsy recommendation comes from a database of over 9000 biopsied lesions from 7000 patients, consisting of in vivo skin lesion images and corresponding histopathologic results.

A recent large multicenter study evaluated the diagnostic accuracy of MelaFind, and found it to have a sensitivity of 98.4% and a specificity superior to that of expert dermatologists using dermoscopy.\textsuperscript{42} In the study, MelaFind had a biopsy ratio of 10.8:1 for melanomas, and a ratio of 7.6:1 for borderline lesions (high-grade dysplastic nevus, atypical melanocytic hyperplasia, and atypical melanocyte proliferation) were also included.\textsuperscript{42} Such a biopsy ratio is better than most ratios from reported literature. An earlier study evaluated the ability of MelaFind to diagnose melanoma in small pigmented lesions (smaller than 6 mm) and showed sensitivity of 98% for melanoma.\textsuperscript{4} This study also showed sensitivity superior to expert dermatologists with similar levels of specificity.

MelaFind was approved for use in Europe in September 2011, and in the United States in November of 2011. In contrast to other devices that have only FDA 510(k) clearance, MelaFind has FDA premarket approval. MelaFind differs from other diagnostic modalities in that it provides the user with a recommendation as to whether or not to biopsy, whereas many other technologies completely rely on user interpretation for the decision to biopsy. As such, MELA Sciences has strict quality controls in place, and would need to maintain ownership of the device to assure that devices are properly updated and maintained. MelaFind is expected to be made available to dermatologists, with doctors paying a one-time fee to lease the
device and receive training. At the time of publication, insurance coverage was not available for use of the device, so this fee will be an out-of-pocket expense to the patient. Given that the price per use is targeted to be less than the cost of biopsy and histopathology, MelaFind could provide a cost-effective means of reducing numbers of biopsies while improving diagnostic accuracy.

**OTHER IMAGING TECHNOLOGIES**

Optical coherence tomography (OCT) is a well-established tool in ophthalmology. OCT is commonly used as a diagnostic aid for uveal melanoma and has shown usefulness in dermatology as well. OCT is analogous to ultrasound imaging, except that it uses light rather than sound waves. OCT uses a low-coherence-length light source to evaluate lesion architecture up to 1 mm in depth. One study showed that OCT allows for in vivo correlation between dermatoscopic parameters and histopathologic analysis in melanocytic lesions.

Resolution in OCT is insufficient to show morphology of single cells, but does allow for evaluation of architectural changes. OCT is further limited, as it has shown inability to properly image lesions that are raised or hyperkeratotic. The resolution in OCT lies between that of ultrasonography and CSLM, and at this point is best suited for measuring depth of invasion rather than diagnosing melanoma.

Reflex transmission imaging (RTI) is a form of high-resolution ultrasonography that can be combined with white-light digital photography to classify pigmented lesions. In one study, RTI was found to discriminate between melanoma, seborrheic keratoses, and nevi based on quantitative methods involving various sonographic parameters. When parameters were set to yield 100% sensitivity for distinguishing melanoma from seborrheic keratoses and benign pigmented lesions, RTI provided 79% specificity for differentiation of seborrheic keratoses from melanoma, and specificity of 55% for differentiating benign pigmented lesions.
from melanoma. RTI has yet to be validated in prospective studies, but results from initial studies warrant further investigation into its clinical applications.

**UPCOMING TECHNOLOGIES**

**Noninvasive Genomic Detection**

Epidermal genetic information retrieval (EGIR; DermTech International, La Jolla, CA, USA) uses an adhesive tape placed on suspicious lesions to sample cells from the stratum corneum noninvasively. RNA isolated from cells is amplified using real-time polymerase chain reaction and then hybridized with Affymetrix human genome U133 plus 2.0 GeneChip. Gene expression is then analyzed. Using this technology, 312 genes that are differentially expressed between melanoma, nevi, and normal skin were identified. Subsequent analysis has reduced the number or genes needed to be analyzed to differentiate melanoma from nevi to 17. The 17 genes used in the analysis are known to be involved in functions such as melanocyte development, pigmentation signaling, hair and skin development, melanoma progression, cell death, cellular development, and cancer. Using this 17-gene classifier, EGIR was able to accurately differentiate between in situ and invasive melanomas from nevi with 100% sensitivity and 88% specificity.

EGIR has many potential advantages. It is noninvasive, and samples can be easily obtained in the office setting. Multiple lesions can be quickly sampled, preventing initial need for biopsies, and in studies to date EGIR has shown high sensitivity and specificity. The major disadvantage is that it requires the tape sample to be sent to a distant laboratory, so results would not be available on the same day as they would be with other imaging technologies. Patients would be required to return at a later date for a biopsy if indicated by the test results, which could raise the possibility of patients being lost to follow-up.

As the RNA analyzed with EGIR is isolated from cells found in the stratum corneum, it is interesting that diagnosis of melanoma can be made by tape stripping, considering the fact that melanocytes generally reside deeper, at the dermal-epidermal junction. It is unclear whether the RNA sampled comes directly from the melanocytes, is due to the effect of melanocytes on surrounding keratinocytes through cell-cell cross-talk, or is a result of pagetoid spread of melanocytes into the epidermis. Regardless of the mechanism, EGIR has great potential and represents a novel technique in diagnosing melanoma, although initial studies are limited by sample size.

**Electrical Impedance Spectroscopy**

Electrical impedance spectroscopy (EIS) is an investigational technology that has shown promise in its ability to assist in diagnosing melanoma. EIS uses an impedance spectrometer probe to measure opposition to flow of alternating currents from one pole to another across a lesion at various frequencies. The probe consists of many microscopic pins designed to penetrate the stratum corneum and pass a low-voltage current to allow measurement of electrical impedance of the tissue. EIS works on the premise that cancer cells have electrochemical properties that are distinct from those of healthy cells. EIS has demonstrated the ability to distinguish different stages of breast cancer cell lines. In vitro studies using cultured mouse melanoma cells show reduced membrane capacitance typical of other types of cancer cells, supporting the possibility the EIS could be useful in melanoma detection.

Two recent in vivo studies evaluated EIS using an automated algorithm to distinguish between melanoma and benign lesions. One study evaluated 62 malignant melanomas and 148 various benign lesions, and showed sensitivity to melanoma of 95% and specificity of 49%. These numbers were similar to results of a previous study that showed sensitivity of 91% and specificity of 64%. While EIS is a promising new technology, it does have limitations and improvements still need to be made. Despite the fact that EIS uses an automated algorithm, it is still somewhat user dependent in accurately providing a diagnosis. The procedure for evaluating a lesion involves soaking the skin in saline solution for 60 seconds before impedance measurement to facilitate better contact between the skin and electrode system. One EIS measurement takes approximately 20 seconds, and measuring an entire lesion typically takes less than 5 minutes. It is also necessary to measure EIS in perilional skin for calibration to compensate for inter-subject variation due to factors such as age, gender, body location, and seasonal variation. In most cases, EIS is more time consuming than a skin biopsy and other diagnostic modalities, and is also more technically challenging. Despite these limitations, its ability to noninvasively analyze a lesion and accurately recommend the need for biopsy make it an intriguing technology for further study.

**Fiber Diffraction**

The α keratins in hair and nail proteins produce a characteristic x-ray fiber diffraction pattern in all mammals, regardless of age or species. Recent studies have shown that some cancers, including melanoma, cause detectable alterations in the
molecular patterns of macromolecules in hair, nails, and skin. A recent blinded retrospective study looking at multiple forms of cancer was able to detect changes in x-ray fiber diffraction from skin samples in all 28 patients diagnosed with melanoma. The diffraction pattern for all melanoma patients had a single additional ring in the same location, which was not appreciated in any of the other 238 patients consisting of controls as well as patients with other cancers or systemic diseases. There is currently no biological mechanism to explain the changes in diffraction patterns, but results have been consistent and specific to the type of malignancy, and have not resulted in any false negatives. Large prospective studies are still needed to clarify sensitivity and specificity, and this technique would only indicate the presence of melanoma somewhere in the patient but would not identify specific lesions of concern. However, fiber diffraction is certainly an intriguing possibility for melanoma detection or screening, particularly in high-risk patients.

**Tissue Elastography**

Real-time tissue elastography is a technology under very early investigation, which is based on the principle that softer, normal tissue deforms more easily than harder, malignant tissue. Lesions are evaluated by manually applying light pressure with an ultrasound transducer with simultaneous imaging by ultrasonography. A recent report showed that tissue elastography was able to correctly identify cutaneous melanoma in 2 patients. Similar to other evaluative methods, tissue elastography is highly operator dependent. It has been shown to be a useful diagnostic tool in the detection of breast cancer and prostate cancer. With further refinement, tissue elastography could someday be an affordable, noninvasive diagnostic tool for diagnosing melanoma.

**Thermal Imaging**

Like many other cancers, melanoma lesions have higher metabolic activity than normal healthy tissue. This property could be exploited using dynamic thermal imaging to examine lesions with infrared imaging. Early results show that there are detectable temperature differences between melanoma and healthy tissue. This technique is currently technically challenging, as the skin must be cooled to accentuate temperature differences and sophisticated motion tracking is needed to compensate for movement of the patient while acquiring thermal images.

**Melanoma-Sniffing Dogs**

A recent study in detection of lung cancer has shown promise in the ability of dogs to detect cancer in patients. In this study, dogs examined 220 exhalation samples from a combination of patients with and without lung cancer. The dogs were able to correctly identify 71% of the samples coming from those with lung cancer, and correctly identified 93% of the samples that were cancer free. A similar study also showed promise with detection of breast cancer from exhalation samples. There have been isolated case reports of dogs identifying skin cancers in patients. In one case, a dog continually showed interest in a mole belonging to its owner, and even tried to bite off the mole, which eventually led the owner to seek medical advice. The mole was excised and found to be invasive melanoma. A similar case was reported in a patient with a lesion later found to be a basal cell carcinoma. The experiences in lung and breast cancer suggest that trained canines may hold promise as aides in the dermatology office for the detection of melanoma, although clinical trials will be needed to see whether the evidence goes beyond anecdotal.

**SUMMARY**

Despite recent advances in the diagnosis and treatment of malignant melanoma, it still remains a potentially devastating disease if not diagnosed early and treated properly. With incidence continuing to increase, advances in diagnostic techniques are necessary because diagnosing melanoma is difficult and current methods still miss too many cases, especially in small-diameter lesions. Moreover, biopsying benign lesions can lead to increased morbidity to patients and increased cost to the health care system. Many available technologies are underutilized, with more promising technologies on the way.

There are significant barriers to implementation that must be overcome, including the time, training, and experience needed to properly use many of these technologies, and costs associated with developing and adopting new technologies. Also, none of these modalities currently are reimbursed by insurance carriers. Ideally new technologies would: (1) have increased sensitivity and specificity in comparison with current methods; (2) be able to be used in a time-efficient manner, such that the time needed to use the diagnostic aid is equivalent to or less than the time it takes to perform a biopsy; (3) have some reimbursement through insurance if proved to decrease the number of benign biopsies performed, to encourage their widespread use; and (4) be accessible to a wide range of patients and physicians, including nondermatologists, as a significant proportion of melanomas are diagnosed by primary care providers and other physicians.
With proper implementation of these technologies, it is hoped that the ultimate goal of reducing the morbidity and mortality associated with melanoma can be reached.

REFERENCES


New Diagnostic Aids for Melanoma

